Dr. Spratt on Combination of Immunotherapy and Radiation in Prostate Cancer

Daniel Eidelberg Spratt, MD
Published: Friday, Feb 17, 2017



Daniel Eidelberg Spratt, MD, assistant professor, radiation oncology, University of Michigan Health System, discusses the combination of immunotherapy and radiation in patients with prostate cancer.

Immunotherapy in patients who have metastatic disease of different types of cancer, have shown great response rates. There are ongoing trials that are focused on combining radiation and immunotherapy to try to release antigens so the immunotherapy knows the cancer should not exist, Spratt explains.

Prostate cancer has had less success than different tumor types, such as multiple myeloma. Some of the initial trials being done have not shown favorable results but the trials are still ongoing, Spratt states.
 
SELECTED
LANGUAGE


Daniel Eidelberg Spratt, MD, assistant professor, radiation oncology, University of Michigan Health System, discusses the combination of immunotherapy and radiation in patients with prostate cancer.

Immunotherapy in patients who have metastatic disease of different types of cancer, have shown great response rates. There are ongoing trials that are focused on combining radiation and immunotherapy to try to release antigens so the immunotherapy knows the cancer should not exist, Spratt explains.

Prostate cancer has had less success than different tumor types, such as multiple myeloma. Some of the initial trials being done have not shown favorable results but the trials are still ongoing, Spratt states.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Oncology Briefings™: Current Perspectives on Preventing and Managing Tumor Lysis SyndromeJun 30, 20191.0
Publication Bottom Border
Border Publication
x